Daniel E. Greenleaf Purchases 16,000 Shares of BioScrip Inc. (BIOS) Stock
BioScrip Inc. (NASDAQ:BIOS) CEO Daniel E. Greenleaf bought 16,000 shares of the business’s stock in a transaction that occurred on Thursday, November 10th. The shares were acquired at an average price of $1.30 per share, with a total value of $20,800.00. Following the transaction, the chief executive officer now directly owns 16,000 shares of the company’s stock, valued at approximately $20,800. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
BioScrip Inc. (NASDAQ:BIOS) opened at 1.39 on Wednesday. BioScrip Inc. has a 12-month low of $1.15 and a 12-month high of $3.43. The stock’s market cap is $163.58 million. The firm’s 50-day moving average price is $2.69 and its 200 day moving average price is $2.66.
BioScrip (NASDAQ:BIOS) last issued its quarterly earnings data on Monday, November 7th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.05) by $0.07. The firm earned $224.50 million during the quarter, compared to analyst estimates of $223.26 million. The firm’s revenue for the quarter was down 9.2% on a year-over-year basis. During the same period in the previous year, the business posted ($0.38) earnings per share. Analysts anticipate that BioScrip Inc. will post ($0.39) EPS for the current year.
Several research firms have weighed in on BIOS. Zacks Investment Research cut BioScrip from a “buy” rating to a “hold” rating in a report on Friday, August 12th. Jefferies Group began coverage on BioScrip in a report on Tuesday, November 8th. They set a “buy” rating and a $2.50 price target for the company.
Several institutional investors have recently modified their holdings of BIOS. BlackRock Advisors LLC boosted its position in shares of BioScrip by 87.8% in the third quarter. BlackRock Advisors LLC now owns 57,715 shares of the company’s stock valued at $167,000 after buying an additional 26,989 shares during the period. Metropolitan Life Insurance Co. NY acquired a new position in BioScrip during the second quarter worth $152,000. Oxford Asset Management acquired a new position in BioScrip during the second quarter worth $176,000. The Manufacturers Life Insurance Company acquired a new position in BioScrip during the third quarter worth $209,000. Finally, PNC Financial Services Group Inc. boosted its position in BioScrip by 368.4% in the second quarter. PNC Financial Services Group Inc. now owns 74,362 shares of the company’s stock worth $190,000 after buying an additional 58,486 shares during the last quarter. 85.85% of the stock is owned by institutional investors and hedge funds.
BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.
Receive News & Stock Ratings for BioScrip Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip Inc. and related stocks with our FREE daily email newsletter.